Anixa Biosciences Announces European Patent On Ovarian Cancer Vaccine Technology
Portfolio Pulse from Benzinga Newsdesk
Anixa Biosciences, Inc. (NASDAQ:ANIX) announced that the European Patent Office intends to grant a patent for its ovarian cancer vaccine technology, which was developed in partnership with Cleveland Clinic. The technology, which targets AMHR2-ED expressed in ovarian cancers, has already been granted a U.S. patent and is being developed with the collaboration of the National Cancer Institute's PREVENT program.
November 27, 2023 | 1:44 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Anixa Biosciences is set to receive a European patent for its ovarian cancer vaccine technology, potentially expanding its market and providing additional intellectual property protection in Europe.
The announcement of the intention to grant a European patent for Anixa's ovarian cancer vaccine technology is likely to be viewed positively by investors, as it represents progress in the company's development pipeline and potential market expansion. The news could increase investor confidence in Anixa's intellectual property and future revenue potential, leading to a short-term positive impact on the stock price.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100